Chargement en cours...
Se connecter/S'inscrire
Bienvenue
Profil
Se déconnecter
texte
titre
titre de chapitre
mot-clé
Page d'accueil de l'OMS
OMS - Systèmes et services de santé
OMS - Médicaments
Sites OMS
Page d'accueil - Publications et documents sur les médicaments
Rechercher
Titres A-Z
Sujets
Mots-clés
Séries et Périodiques
Éditeurs
Auteurs A-Z
Régions
Pays
Index
Sous-collections
Public
sub-collections
Document complet
|
Dérouler chapitre
|
Etendre sommaire
|
Version HTML imprimable
::
Thèmes & Mots-clés
·
Mots-clés
>
pharmaceuticals newsletter
WHO Pharmaceuticals Newsletter 2001, No. 02&03
(2001; 21 pages)
Table des matières
EDITORIAL
REGULATORY MATTERS
ARISTOLOCHIA - Alert against products containing aristolochic acid Canada, USA.
AMIODARONE - Important monograph additions Canada, USA.
BOTULINUM TOXIN - Warning against unauthorised use Ireland.
CANNABIS - Medical use legalized Canada.
CERIVASTATIN - Voluntary withdrawal by Bayer Worldwide.
CLARITHRO-MYCIN - Change of labelling Japan.
EPHEDRA - Serious reactions with other stimulants Canada.
GAMMA HYDROXY BUTYRATE - Fantasy drugs to be classified New Zealand.
ITRACONAZOLE - Labelling changes USA.
LEVACETYL- METHADOL - Suspension of marketing authorisation Europe.
LEVOCARNITINE - Revised labelling USA.
METHADONE - New regulations to promote safer use Germany.
MICONAZOLE - Possible interaction with warfarin prompts labelling changes Canada.
OXYCODONE - Labelling changes to address inappropriate prescribing USA.
PHENYLPROPANOLAMINE (PPA) - Product withdrawal from the market Canada.
PROPOFOL - Not to be used for sedation in paediatric patients USA.
RITUXIMAB - Revised warnings section Canada.
SEIROGAN - OTC remedy and hepatic dysfunction Japan.
TERBINAFINE TABLETS - Revised monograph for usage information Canada, USA.
THIORIDAZINE - QT prolongation risk prompts prescribing update New Zealand.
SAFETY OF MEDICINES
ACICLOVIR & VALACICLOVIR - Reports of Neurotoxicity Sweden.
ALLOPURINOL - Adverse reactions include fatal aplastic anaemia Sweden.
BLEOMYCIN - Vascular complications: a reminder Sweden.
BUPROPION - Early prediction of ADRs following widespread use Australia, Singapore, UK.
CETIRIZINE - Serious liver disorders underlying non-specific symptoms Sweden.
ETHINYL-ESTRADIOL/DESOGESTREL - Fatal pulmonary embolism in patient with risk factors for thrombosis Sweden.
GEMFIBROZIL - Pancreatitis: serious case report Sweden.
LEFLUNOMIDE - Concomitant therapy with methotrexate can precipitate adverse reactions Australia.
NEFAZODONE - Risk of severe liver injury Canada.
NSAIDs - Risk of lower GI tract damage New Zealand.
OMEPRAZOLE - Iron deficiency anaemia: first case report Sweden.
PRAMIPEXOLE & ROPINIROLE - Sleep attacks Canada.
PROPOFOL - Warnings against heart failure with high dosages Norway.
RANITIDINE - Serious haemolytic anaemia in an elderly patient Sweden.
ROSIGLITAZONE - Hepatic and cardiovascular ADRs reported Canada.
SILDENAFIL - Not to be prescribed with nitrates New Zealand.
TRASTUZUMAB - Avoid anthracyclines for 22 weeks following therapy Europe.
FOLLOW-UP
Mesenteric ischaemia during the use of sumatriptan and other triptans
Clopidogrel, agranulocytosis and other blood dyscrasias
Signal follow-up: Itraconazole use during pregnancy
Events
COUNTERFEIT DRUGS
A growing menace Russia, USA.
FEATURE
WHO project on implementation and development of national and regional systems of pharmaco-vigilance in the Newly Independent States of Eastern Europe Prof Vladimir K. Lepakhin, Senior Clinical Adviser, Essential Drugs and Medicines Policy, WHO
WHO Pharmaceuticals Newsletter 2001, No. 02&03
Emplois
|
Chercher
|
Contacts
|
Suggestions
|
RSS
|
Confidentialité
|
Courriels frauduleux
© OMS 2013 - Tous droits réservés
Dernière mise à jour: le 3 mai 2013